- Home
- MQT vs CATX Comparison
MQT vs CATX Comparison
Compare MQT & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQT
- CATX
- Stock Information
- Founded
- MQT 1992
- CATX 1983
- Country
- MQT United States
- CATX United States
- Employees
- MQT N/A
- CATX N/A
- Industry
- MQT Investment Bankers/Brokers/Service
- CATX Medical/Dental Instruments
- Sector
- MQT Finance
- CATX Health Care
- Exchange
- MQT Nasdaq
- CATX Nasdaq
- Market Cap
- MQT 222.2M
- CATX 239.0M
- IPO Year
- MQT N/A
- CATX N/A
- Fundamental
- Price
- MQT $10.06
- CATX $3.49
- Analyst Decision
- MQT
- CATX Strong Buy
- Analyst Count
- MQT 0
- CATX 10
- Target Price
- MQT N/A
- CATX $12.90
- AVG Volume (30 Days)
- MQT 52.5K
- CATX 807.4K
- Earning Date
- MQT 01-01-0001
- CATX 11-11-2025
- Dividend Yield
- MQT 4.60%
- CATX N/A
- EPS Growth
- MQT N/A
- CATX N/A
- EPS
- MQT N/A
- CATX N/A
- Revenue
- MQT N/A
- CATX $1,235,000.00
- Revenue This Year
- MQT N/A
- CATX N/A
- Revenue Next Year
- MQT N/A
- CATX N/A
- P/E Ratio
- MQT N/A
- CATX N/A
- Revenue Growth
- MQT N/A
- CATX N/A
- 52 Week Low
- MQT $8.59
- CATX $1.60
- 52 Week High
- MQT $10.67
- CATX $13.44
- Technical
- Relative Strength Index (RSI)
- MQT 60.76
- CATX 51.86
- Support Level
- MQT $10.03
- CATX $3.33
- Resistance Level
- MQT $10.17
- CATX $3.78
- Average True Range (ATR)
- MQT 0.06
- CATX 0.21
- MACD
- MQT -0.02
- CATX 0.04
- Stochastic Oscillator
- MQT 58.41
- CATX 58.39
About MQT Blackrock MuniYield Quality Fund II Inc.
BLACKROCK MUNIYIELD QUALITY FUND II, INC. is a closed-end fund. Its objective is to provide shareholders with as high a level of current income exempt from federal income taxes as is consistent with its investment policies and prudent investment management. It invests in various sectors such as Transportation, Utilities, Health, County/City/Special District/School District, Education, Housing, Corporate, and Tobacco.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.